Showing all 19 results
Amiodarone Tablet
FreeProduct Composition & Available Strengths
We manufacture Amiodarone in standard, internationally recognized strengths to allow for the intensive loading phase and lower maintenance doses required in cardiology.
Active Ingredient Standard Strengths Primary Clinical Target Amiodarone HCl BP / IP / USP 100 mg Low-Dose Maintenance: For fine-tuned long-term rhythm control and geriatric titration. Amiodarone HCl BP / IP / USP 200 mg Standard Therapy: Used for initial institutional oral loading phases and standard daily maintenance. Amlodipine & Enalapril Maleate Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets to protect the Enalapril Maleate from moisture-induced degradation and to ensure the physical integrity of the combination.
Active Ingredient Strength (Standard) Therapeutic Role Amlodipine (as Besylate) BP/USP 5 mg / 10 mg Calcium Channel Blocker (CCB) Enalapril Maleate BP/USP 5 mg / 10 mg / 20 mg ACE Inhibitor Excipients Q.S. Sodium Stearyl Fumarate / Lactose Lubricant & Stabilizer Amlodipine Besylate & Losartan Potassium Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets. The formulation is optimized for 24-hour efficacy, allowing for convenient once-daily dosing.
Active Ingredient Strength (Standard) Therapeutic Role Amlodipine Besylate BP/USP 5 mg Calcium Channel Blocker (CCB) Losartan Potassium BP/USP 50 mg Angiotensin Receptor Blocker (ARB) Excipients Q.S. Microcrystalline Cellulose / Starch Stabilizing Core Matrix Amlodipine With Lisinopril Dehydrate Tablets
FreeProduct Composition & Strength
We supply this product as Uncoated or Film Coated Tablets. The use of Lisinopril in its Dihydrate form ensures superior stability and predictable dissolution profiles.
Active Ingredient Strength (Standard) Therapeutic Role Amlodipine (as Besylate) BP/USP 5 mg / 10 mg Calcium Channel Blocker Lisinopril (as Dihydrate) BP/USP 5 mg / 10 mg / 20 mg ACE Inhibitor Excipients Q.S. Calcium Phosphate / Mannitol Stabilizing Agents Atenolol & Chlorthalidone Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets. The combination is engineered to maintain therapeutic plasma levels over a 24-hour period, supporting once-daily dosing.
Active Ingredient Strength (Standard) Therapeutic Role Atenolol BP/USP 50 mg / 100 mg Cardioselective Beta-Blocker Chlorthalidone BP/USP 12.5 mg / 25 mg Long-acting Diuretic Excipients Q.S. Magnesium Stearate / Povidone Stabilizing Core Matrix Isosorbide Tablets
FreeProduct Composition & Variants
We supply both Mononitrate and Dinitrate forms in immediate and sustained-release formats.
Variant Type Standard Strengths Primary Clinical Use Isosorbide Mononitrate 10mg, 20mg, 40mg Prophylaxis: Long-term prevention of angina. Isosorbide Dinitrate 5mg, 10mg, 20mg Acute & Chronic: Short and long-term heart failure. Sustained Release (SR) 30mg, 60mg Once-Daily: For improved patient compliance. Lisinopril Tablet
FreeProduct Composition & Available Portfolio Range
We manufacture Lisinopril in exact, compendial strengths calibrated to support initial introductory titration up to high-potency cardioprotective maintenance blocks.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Lisinopril Anhydrous / Dihydrate USP / BP / IP 5 mg Oral Solid Uncoated Tablet Initial Titration: For low-dose introductory management, pediatric hypertension, or initial combination therapy initiation. Lisinopril Anhydrous / Dihydrate USP / BP / IP 10 mg Oral Solid Uncoated Tablet Core Commercial Volume: Standard international baseline daily dose for mild-to-moderate chronic essential hypertension. Lisinopril Anhydrous / Dihydrate USP / BP / IP 20 mg Oral High-Potency Solid Tablet Advanced Cardioprotection: High-strength configuration calibrated for severe heart failure management and post-infarction survival optimization. Losartan Tablet
FreeProduct Composition & Available Strengths
We supply Losartan Potassium across the complete, internationally recognized therapeutic range to facilitate progressive dose titrations and precise maintenance regimens.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Losartan Potassium USP / BP / IP 25 mg Oral Solid Film-Coated Tablet Pediatric & Low-Dose Titration: For introductory pediatric hypertension care or initial combination-therapy building. Losartan Potassium USP / BP / IP 50 mg Oral Solid Film-Coated Tablet Core Commercial Volume: Standard international baseline daily dose for mild-to-moderate chronic essential hypertension. Losartan Potassium USP / BP / IP 100 mg Oral High-Potency Solid Tablet Maximal Saturation Maintenance: For advanced hypertensive management, diabetic nephropathy progression delay, and stroke risk reduction in left ventricular hypertrophy. Nifedipine Tablet
FreeProduct Composition & Structural Formats
We supply Nifedipine in exact, internationally standardized strengths, optimized for immediate-release emergency titration or controlled-release daily maintenance.
Active Ingredient Available Strengths Formulation Mechanism Primary Clinical Target Nifedipine IP / BP / USP 10 mg Immediate or Modified Release Acute Titration / Tocolysis: For rapid blood pressure adjustment or suppression of premature labor. Nifedipine IP / BP / USP 20 mg Sustained / Retard Matrix Daily Maintenance: Continuous 12-to-24-hour plasma concentration for chronic hypertension and angina. Nitroglycerin Tablet
FreeProduct Composition & Available Strengths
We supply Nitroglycerin Sublingual Tablets in exact, internationally calibrated low-dose strengths to allow for immediate rescue titration during acute ischemic episodes.
Active Ingredient Common Name Compendial Title Available Strengths Primary Clinical Target Nitroglycerin (GTN) Glyceryl Trinitrate IP / BP / USP 0.4 mg Standard Rescue Dose: Preferred international standard for immediate acute angina abortion. Nitroglycerin (GTN) Glyceryl Trinitrate IP / BP / USP 0.5 mg High-Threshold Prophylaxis: Calibrated for heavy coronary spasm management or pre-exertion protection. Telmisartan & Atorvastatin Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Bilayer Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of both the hygroscopic ARB and the sensitive Statin.
Active Ingredient Strength Primary Clinical Function Telmisartan USP/Ph.Eur. 40 mg Standard ARB maintenance dose for continuous 24-hour peripheral vasodilation and RAAS blockade. Atorvastatin Calcium USP/Ph.Eur. 10 mg (Equivalent to Atorvastatin base) Standard initiation and maintenance dose for moderate-intensity LDL cholesterol reduction. Excipients Meglumine / Calcium Carbonate / Microcrystalline Cellulose / Magnesium Stearate Alkalizer for Telmisartan / Micro-environment stabilizer for Atorvastatin (Engineered for kinetic segregation) Telmisartan & Chlorthalidone Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Bilayer or Matrix Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of both the hygroscopic ARB and the micro-dosed diuretic.
Active Ingredient Strength Primary Clinical Function Telmisartan USP/Ph.Eur. 40 mg Standard ARB maintenance dose for continuous 24-hour peripheral vasodilation and RAAS blockade. Chlorthalidone USP/Ph.Eur. 6.25 mg Highly precise, long-acting thiazide-like diuresis optimized for maximum safety and efficacy. Excipients Meglumine / Sodium Hydroxide / Microcrystalline Cellulose / Sodium Starch Glycolate Alkalizer for Telmisartan / Diluent / Superdisintegrant (Engineered for kinetic segregation and immediate dissolution) Telmisartan & Metoprolol Succinate Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Bilayer Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of both the hygroscopic ARB and the kinetic polymer matrix.
Active Ingredient Strength Primary Clinical Function Telmisartan USP/Ph.Eur. 50 mg Custom-titrated ARB dose for continuous 24-hour peripheral vasodilation and RAAS blockade. Metoprolol Succinate USP/Ph.Eur. 40 mg (Enteric-Coated / ER) Cardioselective beta-1 blockade for continuous heart rate control and anti-anginal defense. Excipients Meglumine / Methacrylic Acid Copolymer (Enteric Coat) / Microcrystalline Cellulose Alkalizer for Telmisartan / Gastric-resistant polymer for Metoprolol (Engineered for strict kinetic segregation) Telmisartan & Metoprolol Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Bilayer Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of both the hygroscopic ARB and the kinetic polymer matrix.
Active Ingredient Strength Primary Clinical Function Telmisartan USP/Ph.Eur. 40 mg Standard ARB maintenance dose for continuous 24-hour peripheral vasodilation. Metoprolol Succinate USP/Ph.Eur. 25 mg (Extended-Release) Low-dose cardioselective beta-1 blockade for gentle heart rate control and initiation therapy. Excipients Meglumine / Hypromellose (HPMC) / Microcrystalline Cellulose / Sodium Hydroxide Alkalizer for Telmisartan / SR Polymer matrix for Metoprolol (Engineered for kinetic segregation) Telmisartan Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Uncoated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips. The formulation utilizes specialized alkalizing agents to ensure the highly insoluble API rapidly dissolves in the gastrointestinal tract.
Active Ingredient Strength Primary Clinical Use Telmisartan USP/BP/Ph.Eur. 20 mg Initiation / Hepatic Impairment: Low-dose titration for sensitive or hepatically compromised patients. Telmisartan USP/BP/Ph.Eur. 40 mg Standard Global Dose: Once-daily maintenance therapy for essential hypertension. Telmisartan USP/BP/Ph.Eur. 80 mg Maximum CV Protection: High-dose therapy for severe hypertension and mandated cardiovascular risk reduction. Excipients Meglumine / Sodium Hydroxide / Povidone / Magnesium Stearate Alkalizing Stabilizer / Binder / Lubricant (Engineered to prevent API crystallization and ensure rapid absorption) Telmisartan, Amlodipine & Hydrochlorothiazide Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Multi-Layer or Segregated Matrix Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of the hygroscopic ARB and the sensitive CCB.
Active Ingredient Strength Primary Clinical Function Telmisartan USP/Ph.Eur. 40 mg Continuous 24-hour peripheral vasodilation and potassium-sparing RAAS blockade. Amlodipine Besylate USP/Ph.Eur. 5 mg (Equivalent to Amlodipine base) Calcium channel blockade for direct arterial relaxation and anti-anginal defense. Hydrochlorothiazide (HCTZ) USP/Ph.Eur. 12.5 mg Thiazide diuresis for blood volume reduction and mitigation of peripheral edema. Excipients Meglumine / Microcrystalline Cellulose / Sodium Starch Glycolate / Magnesium Stearate Alkalizer for Telmisartan / Diluent / Superdisintegrant (Engineered for kinetic segregation) *Pack Sizes: 10×10 or 10×15 Alu-Alu Blisters (Optimized specifically for strict 30-day chronic cardiology adherence regimens).
Ticagrelor Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Film-Coated Tablet, packed in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of the highly sensitive active pharmaceutical ingredient across all global climate zones.
Active Ingredient Strength Primary Clinical Use Ticagrelor INN/Ph.Eur. 90 mg Acute & Post-ACS: Standard twice-daily dose for the first 12 months following a heart attack or stent placement. Ticagrelor INN/Ph.Eur. 60 mg Extended Maintenance: Long-term prophylaxis for high-risk patients continuing therapy beyond the initial 12-month period. Excipients Mannitol / Dibasic Calcium Phosphate / Sodium Starch Glycolate / Hypromellose Diluent / Superdisintegrant / Film Coating (Engineered for immediate, highly predictable gastric dissolution) Torsemide Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Uncoated Tablet, packed in highly secure, moisture-resistant Alu-PVC or opaque Alu-Alu blister strips, providing dosage flexibility for both mild hypertension and severe renal failure.
Active Ingredient Strength Primary Clinical Use Torsemide USP/Ph.Eur. 5 mg / 10 mg Standard maintenance therapy for mild-to-moderate congestive heart failure and essential hypertension. Torsemide USP/Ph.Eur. 20 mg Acute diuresis for severe hepatic cirrhosis and advanced heart failure exacerbations. Torsemide USP/Ph.Eur. 100 mg High-dose therapy specifically reserved for patients with severe chronic renal failure (CRF) and massive fluid overload. Excipients Lactose Monohydrate / Crospovidone / Magnesium Stearate Diluent / Superdisintegrant / Lubricant (Engineered for immediate, predictable gastric dissolution) Trimetazidine Tablets
FreeProduct Composition & Strength
We supply this product as an advanced Modified-Release (MR) Film-Coated Tablet, packed in highly secure, moisture-resistant Alu-Alu blister strips to ensure the stability of both the active ingredient and the kinetic polymer matrix.
Active Ingredient Strength Primary Clinical Use Trimetazidine Dihydrochloride BP/Ph.Eur. 35 mg (Modified-Release) Global Standard: Twice-daily maintenance therapy for stable angina pectoris. Trimetazidine Dihydrochloride BP/Ph.Eur. 20 mg (Immediate-Release) Three-times-daily dosing for specialized dose titration or specific regional protocols. Excipients Hypromellose (HPMC) / Calcium Hydrogen Phosphate / Magnesium Stearate SR Polymer Matrix / Diluent / Lubricant (Engineered for strict 12-hour kinetic release)
